Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vigabatrin: a three year clinical analysis

P J Martin1, P A Millac

  • 1Department of Neurology, Leicester Royal Infirmary, UK.

Seizure
|June 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammation at the Crossroads: the Combined Effects of COVID-19, Ageing, and Air Pollution.

The Journal of frailty & aging·2021
Same author

Mr. Martin's Case of Imperforate Anus.

The Medical and physical journal·2018
Same author

Mr. Martin, on Cold Affusion in Fever.

The Medical and physical journal·2018
Same author

Observations on Some of the Accidents of Infanticide.

Edinburgh medical and surgical journal·2018
Same author

Biomineralization of osteoblasts on DLC coated surfaces for bone implants.

Biointerphases·2018
Same author

Tuning the plasmonic response of TiN nanoparticles synthesised by the transferred arc plasma technique.

Nanoscale·2018
Same journal

UNC13A-related neurodevelopmental disorders in children: epilepsy phenotypes and antiseizure medication response.

Seizure·2026
Same journal

Switching from oxcarbazepine to eslicarbazepine in patients with focal epilepsy: A systematic review and single-arm meta-analysis.

Seizure·2026
Same journal

Efficacy, tolerability, and EEG lateralization-based predictors of neuropsychiatric adverse events in pediatric SeLECTS treated with perampanel monotherapy.

Seizure·2026
Same journal

Cross-cultural validation of the International Classification of Cognitive Disorders in Epilepsy (IC-CoDE) in Chinese-speaking people with epilepsy.

Seizure·2026
Same journal

Unlocking seizure freedom: A European Delphi panel study on the clinical, humanistic, and economic value of seizure control in epilepsy.

Seizure·2026
Same journal

RLIM variant associated with X-linked epilepsy with neurodevelopmental disorders and the molecular sub-regional effects.

Seizure·2026
See all related articles

Vigabatrin effectively reduced seizure frequency by at least 50% in 36% of severe epilepsy patients. This epilepsy drug showed improved efficacy for tonic-clonic seizures and fewer treatment withdrawals due to adverse effects compared to previous studies.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Severe epilepsy presents significant management challenges.
  • Vigabatrin is an established antiepileptic drug.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of vigabatrin in severe epilepsy patients.
  • To compare vigabatrin's effectiveness for different seizure types.

Main Methods:

  • Retrospective analysis of 57 patients with severe epilepsy treated with vigabatrin.
  • Assessment of seizure frequency reduction and adverse drug reactions.

Main Results:

  • Vigabatrin achieved a ≥50% seizure frequency reduction in 36% of patients.
  • Greater efficacy was observed in primary tonic-clonic seizures compared to complex partial seizures.

Related Experiment Videos

  • Lower rates of treatment withdrawal due to adverse drug reactions were noted compared to prior studies.

    • Conclusions:

    • Vigabatrin is an effective treatment option for severe epilepsy, particularly for tonic-clonic seizures.
    • The drug is generally well-tolerated, with fewer withdrawals than previously reported.
    • Further research may explore optimizing vigabatrin use in specific epilepsy syndromes.